conducted two multicentre, randomised, double-blinded and placebo-controlled trials to evaluate the efficacy of tolvaptan, an oral vasopressin V2 receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia. This evidence concerns the gene AVPR2 and Hyponatremia.